Purpose: To evaluate the real-life safety profile of intravitreal dexamethasone implant injection for various retinal conditions.
Methods: Retrospective multicenter analysis of intravitreal dexamethasone implant injections (700 µg) due to various retinal conditions including central retinal venous occlusion (1861 injections), diabetic macular oedema (3104 injections), post-surgical cystoid macular oedema (305 injections) and uveitis (381 injections). The eyes were evaluated mainly for the occurrence of adverse events such as glaucoma, cataract, retinal detachment and endophthalmitis along during the follow-up period.
Results: A total of 6015 injections in 2736 eyes of 1441 patients (mean age of 65.7±12.9 years) were in total analysed over an average period of 18 months (range 6 months to 102 months). A total of 576 eyes (32.5% of the phakic eyes) developed cataract requiring surgical intervention. However, visually insignificant cataract progression was observed in another 259 phakic eyes (14.6%) which did not require surgical removal. A total of 727 eyes (26.5%) experienced an intraocular pressure (IOP) rise of >25 mm Hg, with 155 eyes (5.67%) having a prior history of glaucoma and 572 eyes (20.9%) having new onset IOP rise. Overall, more than 90% of eyes with IOP rise were managed medically, and 0.5% eyes required filtering surgery. Endophthalmitis (0.07%), retinal detachment (0.03%) and vitreous haemorrhage (0.03%) were rare. There was no significant change in visual acuity (p=0.87) and central macular thickness (p=0.12) at the last follow-up.
Conclusion: This is the largest real-life study assessing the safety of intravitreal dexamethasone implant injections in various retinal conditions. Cataract progression and intraocular pressure rise are the most common side effects, but are often rather easily manageable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjophthalmol-2019-313991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of intravitreal dexamethasone implant (Ozurdex) in patients with post-surgical macular edema - a real-world scenario.
Int J Retina Vitreous
January 2025
Ophthal - Hospital Especializado, São Paulo, SP, Brazil.
Background: Clinically significant macular edema (CME) is the leading cause of visual loss after ophthalmologic surgery due to the release of inflammatory mediators promoted by the procedures. We aimed to evaluate the outcomes of intravitreal Ozurdex (700 µg dexamethasone) implants as a primary therapeutical option for post-surgical macular edema cases.
Methods: Patients with post-surgical macular edema diagnosed by optical coherence tomography (Cirrus SD-OCT) and treated with Ozudex were selected for the current study.
Risk for Ocular Hypertension With Intravitreal Dexamethasone Implants in Black and White Patients With Diabetic Macular Edema.
J Vitreoretin Dis
January 2025
Georgia Retina, Atlanta, GA, USA.
To compare the effects of intravitreal (IVT) 0.7 mg dexamethasone implants on the intraocular pressure (IOP) in Black patients and White patients with diabetic macular edema (DME). A retrospective cohort study was performed of Black patients and White patients with DME who received dexamethasone implants with 12 or more months of follow-up.
View Article and Find Full Text PDFDexamethasone Intravitreal Injection in Diabetic Patients Undergoing Cataract Surgery: an updated literature review.
Retina
January 2025
Ophthalmology Clinic, Department of Biomedical Sciences, University of Messina, Italy.
Purpose: This literature review synthetizes current evidence on the timing and efficacy of dexamethasone intravitreal injections for diabetic macular edema (DME) in patients undergoing cataract surgery, particularly phacoemulsification, to determine the optimal timing for improved outcome.
Methods: A systematic review of the literature was conducted across key databases to identify peer-reviewed studies, clinical trials, and meta-analyses addressing dexamethasone injections administered pre-, intra-, and post-operatively for DME in the context of cataract surgery. Studies were selected based on relevance to timing, visual outcomes, and inflammation control, with a focus on comparative efficacy.
Safety and efficacy of supraciliary dexamethasone implantation for macular oedema: a preliminary comparative study.
Eye (Lond)
January 2025
Department of Ophthalmology, Bursa Uludag University School of Medicine, Bursa, Turkey.
Purpose: To evaluate the efficacy and safety of dexamethasone implantation in the supraciliary (SC) space, a novel and potential effective implantation site, compared to intravitreal (IV) application.
Methods: This prospective study included 39 eyes of 38 patients with macular oedema (ME) who underwent SC and IV dexamethasone implantation (SC-DEX and IV-DEX). Patients were randomly assigned to treatment groups and followed for 3 months.
Advanced pentosan polysulfate sodium maculopathy with low cumulative exposure and hydroxychloroquine use.
Am J Ophthalmol Case Rep
December 2024
Shiley Eye Institute, University of California, San Diego, La Jolla, CA, USA.
Purpose: To report a case of pentosan polysulfate sodium (PPS) maculopathy with cystoid macular edema (CME) with relatively low cumulative PPS exposure and a history of concurrent hydroxychloroquine use.
Observations: A 46-year-old female was treated with PPS daily for 10 years, and hydroxychloroquine intermittently over a span of five years, actively taking hydroxychloroquine for a sum of three years during PPS therapy. Despite a low risk for toxicity based on the cumulative exposure to either medication, fundoscopic examination and multimodal imaging revealed severe PPS maculopathy with CME two and a half years post-PPS cessation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!